Clinical

GLP-1s and Pregnancy: Not Recommended, and the Planning That Follows

GLP-1 receptor agonists are not recommended during pregnancy, and the tirzepatide label notes potential fetal harm based on animal data. Two consequences follow that are

The position

These drugs are not recommended in pregnancy. The tirzepatide label notes that it may cause fetal harm based on animal reproduction studies, and advises discontinuation when pregnancy is recognised.

There is no controlled human trial establishing safety in pregnancy, and there will not be one. That is the normal situation for most medications, and it means the position rests on animal data and the absence of evidence rather than on demonstrated harm in people.

The two consequences people miss

Contraception can be affected during treatment. Tirzepatide reduces absorption of combined oral contraceptives; the label advises a non-oral method or an added barrier method for four weeks after starting and for four weeks after each dose increase. So the drug that should not be continued in pregnancy can reduce the effectiveness of the thing preventing one. Detail on our contraception page.

Fertility can return unexpectedly. In polycystic ovary syndrome, weight reduction can restore ovulation in someone who has not been ovulating and is therefore not tracking cycles or using contraception. That is a route to an unplanned pregnancy in exactly the population most likely to be prescribed these drugs off-label.

We do not publish a washout period. Half-lives differ between these drugs, circumstances differ between patients, and a number published for a general audience would be used by people it does not fit.

Why the timing question needs a clinician

These are long-acting weekly drugs, and the interval between a last dose and clearance is not the same as the dosing interval. The relevant figure differs between tirzepatide and semaglutide, and it interacts with how long you have been taking it.

More importantly, stopping is rarely the whole plan. For someone with type 2 diabetes, glycaemic control during conception and pregnancy is itself clinically critical, so what replaces the GLP-1 matters as much as when it stops. For someone on it for weight management, the withdrawal evidence — 14.0% regain over 52 weeks in SURMOUNT-4 — is relevant to what happens over a conception timeline that may run months.

If you conceive while taking one

Contact your prescriber promptly. The label advises discontinuation when pregnancy is recognised, and there will be decisions about what replaces it.

What this is not is a reason for panic. The position rests on animal data and absent human evidence, not on demonstrated harm in people. That is a meaningful distinction and worth hearing from a clinician who can discuss your specific situation rather than from search results.

Breastfeeding

Safety during breastfeeding is not established. Whether these drugs pass into human milk and what effect that would have has not been characterised, which again places the decision with a clinician weighing the individual situation.

The gap in how this is delivered

A telehealth intake that asks about pregnancy status but not about pregnancy plans, contraception method, or PCOS has covered the box and missed the question. Given that most people on these drugs are of reproductive age and treatment often runs for years, plans change during treatment — which means this needs revisiting, not asking once.

It is a fair question to put to any provider: at what points will you ask me about this again?

Questions readers actually ask